Artes Medical Launches \'\'The ArteFill Face Forward Makeover Contest

Tag : pmma panel
Artes Medical, Inc. (Nasdaq:ARTE), maker of the long-lasting dermalfiller ArteFill(R), is celebrating women's changing lives with theArteFill Face Forward Makeover Contest. Women age 35 and over areinvited to submit personal stories about a current or upcoming timeof personal change. Four winners, selected by a panel of judges,will be honored with makeovers worth approximately $10,000. Allentries must be submitted online at www.myFillosophy.com by July31, 2008.

"Looking your best builds confidence and self-esteem," said contestjudge Eva Ritvo, M.D., psychiatrist and author of the upcomingbook, The Beauty Prescription. "Whether women are embarking on anew career, beginning a new relationship, or entering - gracefully- a new life stage as a grandparent or retiree, I see how theirappearance and their attitude are interconnected. In fact, apositive attitude combined with an enhanced appearance brings womenall kinds of rewards from their environment."

Women are encouraged to submit their stories about an upcoming orcurrent time of personal change or accomplishment. Four grand prizewinning entries will be selected and those women will receive amakeover valued at $10,000, which includes an ArteFill treatmentand other non-surgical procedures from a leading physician, subjectto the physician's determination of the suitability of thecandidate for ArteFill treatment; a professional photo shoot withhair, makeup and wardrobe styling; and a feature on the ArteFillweb site. In addition, up to ten first-prize winners will win anArteFill treatment, subject to their suitability for treatment.

"This makeover contest provides Artes Medical with an opportunityto recognize women as they reach important life milestones andempower them to enter this next phase of their lives with aconfident outlook," said Christopher J. Reinhard, ExecutiveChairman, Artes Medical.

ArteFill is the first and only FDA-approved non-resorbable dermalfiller for the correction of smile line wrinkles. While temporarydermal fillers are absorbed by the body, requiring frequent repeatinjections, ArteFill's patented formula provides the support skinneeds for enduring wrinkle correction in just one or twotreatments.

To submit a story, please go to www.myFillosophy.com. Contestantsmust be women age 35 years or over and legal residents of the U.S.to apply. Complete campaign rules and regulations are available atwww.myFillosophy.com.

About ArteFill

ArteFill is the first and only FDA-approved non-resorbableinjectable dermal filler for the correction of wrinkles known assmile lines or nasolabial folds. The unique PMMA microspheres inArteFill are not absorbed by the body and therefore provide thefirst-of-its-kind support for long-lasting wrinkle correction.

An ArteFill Skin Test is required before initial treatment. Themost common adverse events associated with ArteFill treatment,similar to those observed with other dermal fillers, are lumpiness,persistent swelling or redness and increased sensitivity at theinjection site.

ArteFill is a proprietary formulation comprised ofpolymethylmethacrylate, or PMMA, microspheres and bovine collagen,and is the only PMMA-based injectable product that has beenapproved by the FDA for the treatment of facial wrinkles. ArtesMedical is the sole manufacturer of ArteFill, which is onlyavailable in the United States through Artes Medical, and ArtesMedical has not entered into distribution or licensing arrangementswith any third party for the distribution or sale of ArteFill, orany other PMMA-based dermal filler, outside the United States.

About Artes Medical, Inc.

Artes Medical is a medical aesthetics company focused ondeveloping, manufacturing and commercializing a new category ofaesthetic injectable products for the dermatology and plasticsurgery markets. The Company's initial product, ArteFill, is beingmarketed to men and women as a treatment option for the correctionof nasolabial folds. Additional information about Artes Medical andArteFill is available at www.artesmedical.com and www.artefill.com.

Forward-Looking Statements

This news release contains forward-looking statements that arebased on the Company's current beliefs and assumptions and oninformation currently available to its management. Forward-lookingstatements involve known and unknown risks, uncertainties and otherfactors that may cause the Company's actual results, performance orachievements to be materially different from any future results,performance or achievements expressed or implied by theforward-looking statements. As a result of these risks,uncertainties and other factors, which include the Company'shistory of net losses, its ability to timely raise additional fundsto support its operations, its ability to manage its operatingexpenses, its reliance on its sole FDA-approved product, ArteFill,its limited experience in commercializing ArteFill, its futurereceipt of FDA approval to extend the efficacy period of ArteFillbeyond six months and eliminate the skin test requirement, and therisk that the Company's revenue projections may prove incorrectbecause of unexpected difficulty in generating sales and marketacceptance of ArteFill, readers are cautioned not to place unduereliance on any forward-looking statements included in this pressrelease. A more extensive set of risks and uncertainties is setforth in the Company's SEC filings available at www.sec.gov. Theseforward-looking statements represent beliefs and assumptions onlyas of the date of this news release, and the Company assumes noobligation to update these forward-looking statements publicly,even if new information becomes available in the future.

Artes Medical(R) and ArteFill(R) are registered trademarks of ArtesMedical, Inc.